Closing the HPV Testing Gap Act
Summary
HR8939 is an early-stage bill requiring an NIH study on developing a noninvasive HPV test for men. It authorizes no direct funding and has no direct market impact on publicly traded companies at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8939 is a study-only bill with no funding authorization.
- 2.No direct impact on any publicly traded company at this stage.
- 3.Legislative path is long: committee review, potential amendments, House vote, Senate companion, and appropriations.
Market Implications
No near-term market implications. If the bill advances, diagnostic companies such as Quest Diagnostics ($DGX) and Laboratory Corporation of America ($LH) could eventually benefit from test development contracts, but that is years away and contingent on appropriations.
Full Analysis
The Closing the HPV Testing Gap Act (HR8939) was introduced on May 20, 2026, and referred to the House Committee on Energy and Commerce. It is in the earliest legislative stage with no committee hearings or markups. The bill directs the NIH to conduct a study and report to Congress within 24 months on developing a standardized, noninvasive HPV test for men. It does not authorize or appropriate any specific funding amount—it is a study mandate only. No companies are directly named or affected. The bill's impact on markets is negligible until it advances to authorizing actual test development or procurement. The sponsor, Rep. McIver, is a junior member, and with only 10 cosponsors, momentum is low. No real market data is provided for healthcare diagnostics companies, and no tickers meet the confidence threshold for inclusion.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.